CL2004001470A1 - Procedimiento de preparacion de derivados de [(benzoimidazol-1-il)-quinolin-8-il]-piperidin-4-ilamina, utiles en el tratamiento del crecimiento celular anormal, por desproteccion del grupo boc con un alcoxido de metal en presencia de un equivalente d - Google Patents

Procedimiento de preparacion de derivados de [(benzoimidazol-1-il)-quinolin-8-il]-piperidin-4-ilamina, utiles en el tratamiento del crecimiento celular anormal, por desproteccion del grupo boc con un alcoxido de metal en presencia de un equivalente d

Info

Publication number
CL2004001470A1
CL2004001470A1 CL200401470A CL2004001470A CL2004001470A1 CL 2004001470 A1 CL2004001470 A1 CL 2004001470A1 CL 200401470 A CL200401470 A CL 200401470A CL 2004001470 A CL2004001470 A CL 2004001470A CL 2004001470 A1 CL2004001470 A1 CL 2004001470A1
Authority
CL
Chile
Prior art keywords
disprotection
ilamine
benzoimidazol
quinolin
piperidin
Prior art date
Application number
CL200401470A
Other languages
English (en)
Inventor
Jacqueline Tom David Har Norma
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CL2004001470A1 publication Critical patent/CL2004001470A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
CL200401470A 2003-06-24 2004-06-14 Procedimiento de preparacion de derivados de [(benzoimidazol-1-il)-quinolin-8-il]-piperidin-4-ilamina, utiles en el tratamiento del crecimiento celular anormal, por desproteccion del grupo boc con un alcoxido de metal en presencia de un equivalente d CL2004001470A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48217603P 2003-06-24 2003-06-24

Publications (1)

Publication Number Publication Date
CL2004001470A1 true CL2004001470A1 (es) 2005-05-13

Family

ID=33539339

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401470A CL2004001470A1 (es) 2003-06-24 2004-06-14 Procedimiento de preparacion de derivados de [(benzoimidazol-1-il)-quinolin-8-il]-piperidin-4-ilamina, utiles en el tratamiento del crecimiento celular anormal, por desproteccion del grupo boc con un alcoxido de metal en presencia de un equivalente d

Country Status (24)

Country Link
US (2) US7183414B2 (es)
EP (1) EP1641780B1 (es)
JP (1) JP2007516168A (es)
KR (2) KR100787649B1 (es)
CN (1) CN100404530C (es)
AR (1) AR044849A1 (es)
AT (1) ATE414077T1 (es)
AU (1) AU2004249511B2 (es)
BR (1) BRPI0411794A (es)
CA (1) CA2529032C (es)
CL (1) CL2004001470A1 (es)
CO (1) CO5650165A2 (es)
DE (1) DE602004017731D1 (es)
DK (1) DK1641780T3 (es)
ES (1) ES2315663T3 (es)
IL (1) IL172064A (es)
MX (1) MXPA05014203A (es)
NO (1) NO20060376L (es)
NZ (2) NZ543714A (es)
RU (1) RU2323214C2 (es)
SG (1) SG161745A1 (es)
TW (1) TWI294425B (es)
WO (1) WO2004113322A1 (es)
ZA (1) ZA200509253B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
WO2006038111A1 (en) * 2004-10-07 2006-04-13 Pfizer Products Inc. Benzoimidazole derivatives useful as antiproliferative agents
JP2008534689A (ja) * 2005-04-05 2008-08-28 ファーマコペイア， インコーポレイテッド 免疫抑制のためのプリン及びイミダゾピリジン誘導体
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
WO2010121675A2 (en) 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
CN101993416B (zh) * 2009-08-27 2013-09-11 中国科学院上海药物研究所 喹啉类化合物、其制备方法、包含该化合物的药物组合物及该化合物的用途
KR101738063B1 (ko) 2012-09-21 2017-05-19 아로그 파마슈티칼스, 인코퍼레이티드 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
US11642340B2 (en) 2012-09-26 2023-05-09 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
US10835525B2 (en) 2012-09-26 2020-11-17 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
BR112015016282A2 (en) 2013-01-07 2017-07-11 Arog Pharmaceuticals, Inc. crenolanib for treatment of mutated flt3 proliferative disorders
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
US12534764B2 (en) 2016-11-02 2026-01-27 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
EA201991078A1 (ru) 2016-11-02 2019-11-29 Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
CN107382984B (zh) * 2017-08-24 2020-07-10 扬州市三药制药有限公司 一种治疗白血病药物的制备方法
CN107382983B (zh) * 2017-08-24 2020-08-07 扬州市三药制药有限公司 一种治疗白血病药物的合成方法
CN110840893A (zh) 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途
CN109678849A (zh) * 2019-01-16 2019-04-26 北京悦康科创医药科技股份有限公司 一种抗癌药物的制备方法
US11471451B2 (en) 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
CN117447376A (zh) * 2019-12-09 2024-01-26 苏州恩华生物医药科技有限公司 连双环结构sigma-1受体抑制剂
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
CA3186319A1 (en) * 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
CN116234549B (zh) * 2020-08-05 2025-11-25 总医院公司 盐诱导激酶抑制剂
US20220079934A1 (en) * 2020-09-17 2022-03-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pain
US11524006B2 (en) 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
WO2022090547A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. Production of carotenoids by fermentation
CN113683594B (zh) * 2021-09-07 2022-12-27 曲靖师范学院 一种喹啉-苯并咪唑盐类化合物及其合成方法和应用
JP2023063189A (ja) 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897401A (en) * 1987-06-19 1990-01-30 Janssen Pharmaceutical N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful in treating allergic diseases
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
ES2300119T3 (es) * 1997-02-27 2008-06-01 Takeda Pharmaceutical Company Limited Compuestos de amina, su produccion y su uso como inhibidores de la produccion de beta-amiloide.
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
EP1245390A4 (en) * 1999-12-10 2009-04-01 Fujifilm Corp INK JET HEAD AND PRINTER
JPWO2002022549A1 (ja) * 2000-09-14 2004-01-22 鐘淵化学工業株式会社 ニトロベンゼンスルホニル基を除去する方法
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos

Also Published As

Publication number Publication date
JP2007516168A (ja) 2007-06-21
EP1641780B1 (en) 2008-11-12
MXPA05014203A (es) 2006-02-24
IL172064A (en) 2011-01-31
ATE414077T1 (de) 2008-11-15
NZ571898A (en) 2010-01-29
KR20070092333A (ko) 2007-09-12
TWI294425B (en) 2008-03-11
KR20060012033A (ko) 2006-02-06
WO2004113322A1 (en) 2004-12-29
CA2529032C (en) 2009-12-22
DE602004017731D1 (de) 2008-12-24
AR044849A1 (es) 2005-10-05
DK1641780T3 (da) 2009-02-02
CA2529032A1 (en) 2004-12-29
TW200517393A (en) 2005-06-01
RU2323214C2 (ru) 2008-04-27
AU2004249511A1 (en) 2004-12-29
US20070088032A1 (en) 2007-04-19
SG161745A1 (en) 2010-06-29
ES2315663T3 (es) 2009-04-01
NO20060376L (no) 2006-01-24
NZ543714A (en) 2009-06-26
US20050020625A1 (en) 2005-01-27
EP1641780A1 (en) 2006-04-05
RU2005138367A (ru) 2006-08-10
BRPI0411794A (pt) 2006-08-08
HK1089170A1 (en) 2006-11-24
CN1809556A (zh) 2006-07-26
CN100404530C (zh) 2008-07-23
KR100787649B1 (ko) 2007-12-21
ZA200509253B (en) 2007-01-31
US7183414B2 (en) 2007-02-27
CO5650165A2 (es) 2006-06-30
AU2004249511B2 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
CL2004001470A1 (es) Procedimiento de preparacion de derivados de [(benzoimidazol-1-il)-quinolin-8-il]-piperidin-4-ilamina, utiles en el tratamiento del crecimiento celular anormal, por desproteccion del grupo boc con un alcoxido de metal en presencia de un equivalente d
IL183568A (en) Process for making 7,8-dihydro-5 h-patridine-6-onh
IL190997A0 (en) New highly stable aqueous solution, electrode with nanocoating for preparing the solution and method for making this electrode
EP2546246A3 (en) Compounds and methods for the treatment or prevention of flavivirus infections
IL182177A0 (en) Process for preparing 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
IL185108A0 (en) Processes for preparing cinacalcet hydrochloride crystal form i
IL184175A (en) Sulfonyl pyrrolidines, method for producing the same and their use as drugs
HUS1400056I1 (hu) Glükopiranozil-helyettesített benzol-származékok, az említett vegyületeket tartalmazó gyógyszerek, azok alkalmazása, és eljárás elõállításukra
MY152992A (en) Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP1715799A4 (en) METHOD FOR TREATING GLAUCOMA
IL187235A0 (en) 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
PT1720832E (pt) Processo de preparação de derivados de 4-cetoprolina n-protegidos
ITMI20030900A1 (it) Macchina circolare per maglieria, particolarmente per la
IL172899A0 (en) Heterocyclically substituted pentanol derivatives, method for the production thereof, and use thereof as anti-inflammatory agents
IL188431A0 (en) Process for preparing 3-arylmethylthio-and 3-heteroarylmethylthio-4,5-dihydro-
IL197758A0 (en) Novel benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof
PL377864A1 (pl) Pochodne 1-N-(fenylo)-2-N-(fenylo)pirazolidyno-1,2-dikarboksyamidowe jako inhibitory czynnika koagulacyjnego Xa do leczenia zakrzepic
IL186748A0 (en) 4 - phenyl - 5 - oxo 1, 4, 5, 6, 7, 8 - hexahydroquinoline derivatives for the treatment of infertility
ZA200706646B (en) Brown algae cell lyophilisate, method for the obtention thereof
TW200800969A (en) Compounds
IL181832A0 (en) Alkylidene tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
WO2007076159A3 (en) Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
MA28635B1 (fr) Methode de production de derives de 1, 4-diphenylazetidinone
ATE460938T1 (de) Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion